Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race-Ethnicity: A SEER-Medicare Study

被引:2
|
作者
Herbach, Emma L. [1 ,2 ,6 ]
Nash, Sarah H. [1 ]
Lizarraga, Ingrid M. [3 ]
Carnahan, Ryan M. [1 ]
Wang, Kai [4 ]
Ogilvie, Amy C. [1 ]
Curran, Michaela [5 ]
Charlton, Mary E. [1 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL USA
[3] Univ Iowa, Carver Coll Med, Dept Surg, Iowa City, IA USA
[4] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA
[5] Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA
[6] 145 N Riverside Dr CPHB, Iowa City, IA 52242 USA
关键词
RACIAL DISPARITIES; OLDER WOMEN; SURVIVAL; RACE/ETHNICITY; AMERICAN; OUTCOMES; THERAPY; TUMOR; SURVEILLANCE; QUALITY;
D O I
10.1158/1055-9965.EPI-23-0218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Racial and ethnic disparities in guideline-recommended breast cancer treatment are well documented, however studies including diagnostic and staging procedures necessary to determine treatment indications are lacking. The purpose of this study was to characterize patterns in delivery of evidence-based services for the diagnosis, clinical workup, and first-line treatment of breast cancer by race-ethnicity.Methods: SEER-Medicare data were used to identify women diagnosed with invasive breast cancer between 2000 and 2017 at age 66 or older (n = 2,15,605). Evidence-based services included diagnostic procedures (diagnostic mammography and breast biopsy), clinical workup (stage and grade determination, lymph node biopsy, and HR and HER2 status determination), and treatment initiation (surgery, radiation, chemotherapy, hormone therapy, and HER2-targeted therapy). Poisson regression was used to estimate rate ratios (RR) and 95% confidence intervals (CI) for each service.Results: Black and American Indian/Alaska Native (AIAN) women had significantly lower rates of evidence-based care across the continuum from diagnostics through first-line treatment compared to non-Hispanic White (NHW) women. AIAN women had the lowest rates of HER2-targeted therapy and hormone therapy initiation. While Black women also had lower initiation of HER2-targeted therapy than NHW, differences in hormone therapy were not observed.Conclusions: Our findings suggest patterns along the continuum of care from diagnostic procedures to treatment initiation may differ across race-ethnicity groups.Impact: Efforts to improve delivery of guideline-concordant treatment and mitigate racial-ethnic disparities in healthcare and survival should include procedures performed as part of the diagnosis, clinical workup, and staging processes.
引用
收藏
页码:1312 / 1322
页数:11
相关论文
共 36 条
  • [1] Treatment patterns and costs following metastatic breast cancer diagnosis in US women: A SEER-Medicare analysis
    Taylo, D. C. A.
    Sanon, M.
    Clements, K.
    Balu, S.
    Faria, C.
    Teitelbaum, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study
    Pinheiro, Laura C.
    Soroka, Orysya
    Kern, Lisa M.
    Leonard, John P.
    Safford, Monika M.
    [J]. CANCER, 2020, 126 (08) : 1727 - 1735
  • [3] SURVIVAL AND COST OF CARE BY TYPE OF FIRST-LINE THERAPY IN METASTATIC NON-SMALL LUNG CANCER USING SEER-MEDICARE DATA
    Danese, M.
    Lee, A.
    Su, I. H.
    Penrod, J. R.
    Yuan, Y.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S21 - S21
  • [4] Temporal Association Rule Mining: Race-Based Patterns of Treatment-Adverse Events in Breast Cancer Patients Using SEER-Medicare Dataset
    Adam, Nabil
    Wieder, Robert
    [J]. BIOMEDICINES, 2024, 12 (06)
  • [5] Guideline-concordant breast cancer care by patient race and ethnicity accounting for individual-, facility- and area-level characteristics: a SEER-Medicare study
    Herbach, Emma L.
    Curran, Michaela
    Roberson, Mya L.
    Carnahan, Ryan M.
    Mcdowell, Bradley D.
    Wang, Kai
    Lizarraga, Ingrid
    Nash, Sarah H.
    Charlton, Mary
    [J]. CANCER CAUSES & CONTROL, 2024, 35 (07) : 1017 - 1031
  • [6] First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study
    Rodday, Angie Mae
    Hahn, Theresa
    Kumar, Anita J.
    Lindenauer, Peter K.
    Friedberg, Jonathan W.
    Evens, Andrew M.
    Parsons, Susan K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (02) : 222 - 235
  • [7] First-line chemotherapy for breast cancer patients by site of care (SOC): Treatment patterns, cost and quality indicators
    Masaquel, A.
    Hopson, S.
    Casebeer, A.
    Drzayich-Jankus, D.
    Tao, Z.
    Stemkowski, S.
    Howe, A.
    Patton, J.
    Small, A.
    Barnett, B.
    [J]. CANCER RESEARCH, 2016, 76
  • [8] Temporal trends in first-line chemotherapy treatment among elderly stage IIIB/IV non-small cell lung cancer (NSCLC) patients in the United States: Evidence from SEER-Medicare data
    Lang, K.
    Marciniak, M. D.
    Faries, D.
    Stokes, M.
    Buesching, D.
    Earle, C.
    Treat, J.
    Thompson, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] SEER-Medicare study of early-stage triple-negative breast cancer: Real-world treatment patterns, survival, and expenditures 2010 to 2016.
    Sieluk, Jan
    Haiderali, Amin
    Huang, Min
    Yang, Lingfeng
    Tryfonidis, Konstantinos
    Hirshfield, Kim M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Impact onMedical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Danese, Mark D.
    [J]. JOURNAL OF CANCER EPIDEMIOLOGY, 2012, 2012